Cases & Deals

  • Home
  • Practices
  • Celgene develops European patent portfolio covering protein-bound nanoparticle technology (Nab®)

Share

Celgene develops European patent portfolio covering protein-bound nanoparticle technology (Nab®)

October 2019

Client(s) Celgene Corporation

Jones Day represented Celgene Corporation in successfully obtaining numerous European patents relating to one of its platform technologies, namely protein-bound nanoparticles (Nab®). The patents cover pharmaceutical compositions and formulations comprising such nanoparticles, and medical applications thereof including medical conditions, patient populations, and dosage regimens.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.